Media history about Antares Pharma (NASDAQ: ATRS) has been somewhat positive this week, reports Accern Sentiment. The research agency identifies positive and negative news coverage in the press by monitoring more than 20 million news and blog sources in real time. Accern ranks the coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Antares Pharma earned an impact score of 0.22 on the Accern scale. Accern also gave news articles about the specialized pharmaceutical company an impact score of 45,6187,440,139,829 out of 100, indicating that the recent news coverage in the press will have little effect on the share price of the share over the next few days.
Stocks of ATRS shares opened Friday at $ 3.54. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.33 and a quick ratio of 1.89. The shares have a market capitalization of $ 557.33 million, a PE ratio of -32.18 and a beta of 0.19. Antares Pharma has a year low of $ 1.58 and a year of $ 4.09.
Antares Pharma (NASDAQ: ATRS) posted its results for the last time on Tuesday 7 August. The specialized pharmaceutical company reported ($ 0.03) Earnings per Share (EPS) for the quarter, with consensus analysts' estimates ($ 0.02) missing ($ 0.01). Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. The company had sales of $ 14.16 million for the quarter compared to the consensus estimate of $ 13.70 million. sell-side analysts expect Antares Pharma to achieve a profit per share of -0.1 in the current fiscal year.
Several brokers have recently issued reports on ATRS. HC Wainwright set a target price of $ 5.00 on Antares Pharma shares and gave the share a "buy" score in a research report on Friday, August 17. BidaskClub has downgraded Antares Pharma shares from a "strong buy" rating to a "buy" rating in a research report on Wednesday, May 23. Piper Jaffray Companies repeated a "buy" rating and set a target price of $ 4.00 on Antares Pharma shares in a research report on Friday, August 17. Finally, ValuEngine Antares Pharma reduced from a "buy" classification to a "hold" rating in a research note on Thursday 2 August.
In other news, CEO Robert F. Apple sold 43,000 shares of the company's shares in a transaction that took place on Tuesday, August 21st. The shares were sold at an average price of $ 3.75 for a total transaction of $ 161,250.00. After the completion of the transaction, the chief executive officer now holds directly 1,573,562 shares in the company's shares, valued at approximately $ 5,900,857.50. The sale is disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Jacques Gonella also sold 49,507 shares of the company in a transaction that took place on Monday 13 August. The stock was sold at an average price of $ 3.09 for a total transaction of $ 152,976.63. After the transaction, the director now holds directly 9,985,848 shares of the company's shares, valued at $ 30,856,270.32. The information for this sale can be found here. In the past three months, insiders have sold 800,177 shares in the company's shares to the value of $ 2,308,240. 12.20% of the stock is owned by insiders of companies.
About Antares Pharma
Antares Pharma, Inc., a specialized pharmaceutical company, focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP, which consists of a pre-filled methotrexate syringe and a VIBEX self-injection system to enable patients with rheumatoid arthritis (RA) and psoriasis to self-inject methotrexate at home; and Sumatriptan injection USP for the acute treatment of migraine and cluster headache in adults.
Featured article: dividend shares – are they suitable for you?
Receive news and ratings for Antares Pharma Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Antares Pharma and related companies with the FREE daily email newsletter from MarketBeat.com.